SEC 13F Intelligence

Managers / Q2 2024 · view latest →

M28 Capital Management LP

CIK 0001807489 · 700 CANAL STREET, 1ST FLOOR, STAMFORD, CT, 06902 · 203-516-3730

Reported Value
$77M
Q2 2024
Positions
11
Filings on Record
18
2019–present window
Filed
Aug 13, 2024
original filing

Summary

M28 Capital Management LP reported $77M in U.S.-listed holdings across 11 positions for Q2 2024.

The portfolio is heavily concentrated: WVE alone accounts for 39.9% of reported value.

The book was largely unchanged from Q1 2024.

Portfolio Metrics

Turnover
+0.4%
vs prior filed quarter
Top-10 Concentration
+97.8%
share of reported value
Largest Position
+39.9%
Wave Life Sciences

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $128MQ4 ’21Q1 ’22: $109MQ2 ’22: $89MQ3 ’22: $96MQ3 ’22Q4 ’22: $105MQ1 ’23: $88MQ2 ’23: $76MQ2 ’23Q3 ’23: $87MQ4 ’23: $121MQ1 ’24: $135MQ1 ’24Q2 ’24: $77MQ3 ’24: $91MQ4 ’24: $102MQ4 ’24Q1 ’25: $73MQ2 ’25: $59MQ3 ’25: $68MQ3 ’25Q4 ’25: $138MQ1 ’26: $54Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 93.2%ADR: 4.6%Other: 2.2%
  • Common Stock · 93.2% · $72M
  • ADR · 4.6% · $4M
  • Other · 2.2% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SLNSILENCE THERAPEUTICS PLCTRIMMED−114.3K185.1K−$3M$4M
WVEWAVE LIFE SCIENCES LTDTRIMMED−835.5K6.16M−$12M$31M
IVVDINVIVYD INCHELD+09.25M−$31M$10M
GUTSFRACTYL HEALTH INCHELD+01.86M−$6M$8M
RCKTROCKET PHARMACEUTICALS INCHELD+0385.7K−$2M$8M
CURIS INCHELD+0422.0K−$2M$3M
SPRINGWORKS THERAPEUTICS INCHELD+0110.4K−$1M$4M
BBIOBRIDGEBIO PHARMA INCHELD+0121.2K−$677,508$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

11 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1WVEWAVE LIFE SCIENCES LTDhistory →SHS39.88%$31M6.16M
2IVVDINVIVYD INChistory →COM13.19%$10M9.25M
3RCKTROCKET PHARMACEUTICALS INChistory →COM10.76%$8M385.7K
4GUTSFRACTYL HEALTH INChistory →COM10.27%$8M1.86M
5SPRINGWORKS THERAPEUTICS INCCOM5.39%$4M110.4K
6SLNSILENCE THERAPEUTICS PLChistory →ADS4.56%$4M185.1K
7BBIOBRIDGEBIO PHARMA INChistory →COM3.98%$3M121.2K
8CURIS INCCOM3.77%$3M422.0K
9TGTXTG THERAPEUTICS INChistory →COM3.73%$3M161.6K
10ARWRARROWHEAD PHARMACEUTICALS INhistory →COM2.27%$2M67.4K
11PROQR THRAPEUTICS N VSHS EURO2.19%$2M1.02M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$54M9May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$138M9Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$68M9Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$59M9Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$73M11May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$102M11Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$91M11Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$77M11Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$135M11May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M10Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$87M11Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$76M12Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$88M14May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M14Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$96M12Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$89M13Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$109M13May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$128M12Feb 11, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.